

SLOVAK MYELOMA SOCIETY  
The constitution of non-governmental organization

*ARTICLE I.*  
*DESIGNATION, JURIDICAL STATUS, SEAT*

1. The non-governmental organization Slovak Myeloma Society is a volunteer nonprofit association of subjects (in text also “association”) established in accordance with the law No: 83/1990 as amended by later regulations and supplements.  
The **designation** of the non-governmental organization is: **Slovak Myeloma Society** (in text also **SMyS**).
2. Slovak Myeloma Society is a body corporate with competence on the whole territory of Slovak Republic.
3. The **Seat** of the Slovak Myeloma Society is: **Antolská 11, 851 07 Bratislava, Slovak Republic.**

*ARTICLE II.*  
*THE OBJECTIVES OF ACTIVITY*

The objectives of activity of the association are as follows:

1. To support the patients with multiple myeloma and related diseases (further in text just “myeloma”), to support their families and relatives, these patients’ health support and protection.
2. To educate the patients, their relatives, doctors, nurses, healthcare workers and other interested people and increase their awareness about the latest knowledge in the field of myeloma.
3. To collaborate with Slovak and foreign organizations which have similar scope and to support their activities.
4. Fundraising to finance the activities, execution of which is necessary in order to meet the objectives mentioned in this article of the constitution. Slovak Myeloma Society will issue their own educational and promotional materials, as a part of their activity.
5. To make and run an anonymous register of Slovak patients with myeloma. The personal data of individual patients will not be available, only their clinical conditions.
6. To design their own clinical studies and special therapeutic regimens in order to optimize the therapy for as large number of patients as possible.

7. To create a functioning network of regional and university clinics offering care to patients with myeloma.
8. To take part in international multicenter studies.
9. To create guidelines and recommendations for optimum therapy, comparable to that in other countries of EU.
10. To support the research in the field of myeloma.